Trial Profile
A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2013
Price :
$35
*
At a glance
- Drugs Darexaban (Primary) ; Warfarin
- Indications Thromboembolism
- Focus Therapeutic Use
- Acronyms PEARL
- Sponsors Astellas Pharma
- 26 May 2010 Actual patient number (21) added as reported by ClinicalTrials.gov.
- 01 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2009 Additional location (Canada) identified as reported by ClinicalTrials.gov.